NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PLRX

Pliant Therapeutics Inc

Jul 03 • 03:40PM ET

1.26

Dollar change +0.06
Percentage change 5.00	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT BMRN ALNY IONS BLUE ARWR RARE CRSP SGMO

| Held by: VTI VXF IBB VTWO SCHA VFVA IWM VHT IWC PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.61	Insider Own	11.97%	Shs Outstand	61.39M	Perf Week	-3.08%
Market Cap	77.34M	Forward P/E	-	EPS next Y	-1.91	Insider Trans	-1.79%	Shs Float	54.04M	Perf Month	-21.25%
Enterprise Value	-168.13M	PEG	-	EPS next Q	-0.68	Inst Own	86.94%	Short Float	6.23%	Perf Quarter	-10.64%
Income	-219.51M	P/S	-	EPS this Y	28.84%	Inst Trans	-11.65%	Short Ratio	2.93	Perf Half Y	-90.15%
Sales	0.00M	P/B	0.30	EPS next Y	22.52%	ROA	-50.67%	Short Interest	3.36M	Perf YTD	-90.43%
Book/sh	4.19	P/C	0.25	EPS next 5Y	31.14%	ROE	-63.22%	52W High	16.10 -92.17%	Perf Year	-88.40%
Cash/sh	4.98	P/FCF	-	EPS past 3/5Y	-8.59% -78.30%	ROIC	-69.34%	52W Low	1.10 14.54%	Perf 3Y	-83.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.18% 8.69%	Perf 5Y	-96.03%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-26.35%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.03	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	43.31	Recom	2.78
Dividend Gr. 3/5Y	- -	Current Ratio	11.03	EPS Q/Q	-17.59%	SMA20	-7.42%	Beta	1.41	Target Price	5.08
Payout	-	Debt/Eq	0.23	Sales Q/Q	-	SMA50	-10.83%	Rel Volume	1.03	Prev Close	1.20
Employees	171	LT Debt/Eq	0.23	Earnings	May 08 AMC	SMA200	-82.72%	Avg Volume	1.15M	Price	1.26
IPO	Jun 03, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.98% -	Trades		Volume	1,119,900	Change	5.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Resumed	Cantor Fitzgerald	Neutral
Mar-04-25	Downgrade	Needham	Buy → Hold
Mar-03-25	Downgrade	Stifel	Buy → Hold
Mar-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-10-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$41 → $4
Feb-10-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$45 → $4
Feb-10-25	Downgrade	Oppenheimer	Outperform → Perform
Feb-10-25	Downgrade	JP Morgan	Overweight → Neutral
Feb-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-10-25	Downgrade	Citigroup	Buy → Neutral	$40 → $4
Feb-10-25	Downgrade	Canaccord Genuity	Buy → Hold	$43 → $4
Sep-09-24	Resumed	Leerink Partners	Outperform	$46 → $33
Dec-08-23	Initiated	Wells Fargo	Overweight	$41
May-18-23	Initiated	Canaccord Genuity	Buy	$48
Apr-13-23	Initiated	Robert W. Baird	Outperform	$44
Dec-14-22	Initiated	Stifel	Buy	$33
Dec-07-22	Initiated	JP Morgan	Overweight	$42
Sep-01-22	Initiated	Citigroup	Buy	$36
Jul-20-22	Initiated	SVB Leerink	Outperform	$33
May-25-22	Initiated	Cantor Fitzgerald	Overweight	$28

Show Previous Ratings

Jun-30-25 07:43AM	Pliant halts bexotegrast development for IPF after trial results (Clinical Trials Arena) -7.20%
Jun-27-25 04:05PM	Pliant Therapeutics Provides Update on BEACON-IPF (GlobeNewswire)
May-21-25 04:03PM	Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference (GlobeNewswire)
May-08-25 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-02-25 12:35PM	Pliant cuts workforce by 45% following lung trial termination (Clinical Trials Arena)
07:02AM	Loading…
07:02AM	Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma (BioPharma Dive)
May-01-25 04:05PM	Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations (GlobeNewswire)
Apr-10-25 12:00PM	PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-07-25 04:05PM	Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference (GlobeNewswire) -6.72%
Apr-03-25 12:22PM	Pliant Therapeutics: An Activist On Deck (Seeking Alpha) -7.09%
Mar-27-25 09:39AM	PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know (Zacks)
Mar-17-25 08:00AM	Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors (GlobeNewswire) +10.39%
Mar-14-25 07:57AM	Makary advances to full senate vote; Acelyrin, Pliant adopt poison pills (BioPharma Dive)
Mar-13-25 07:20AM	Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement (GlobeNewswire)
Mar-04-25 07:23AM	Pliant Therapeutics stock tumbles amid IPF trial cancellation (Clinical Trials Arena)
06:25AM	Loading…
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results (GlobeNewswire) -59.88%
09:27AM	Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Feb-14-25 12:00PM	All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy (Zacks) -7.60%
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive) +20.96%
08:00AM	Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Feb-11-25 09:11AM	Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan (TipRanks) -15.15%
Feb-10-25 01:15PM	Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive (GuruFocus.com) -60.59%
08:32AM	Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues (Benzinga)
Feb-07-25 04:58PM	Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire) -34.81%
Jan-22-25 04:00PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer (GlobeNewswire)
Jan-02-25 08:00AM	Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Nov-18-24 06:00PM	Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting 2024 (GlobeNewswire)
04:05PM	Loading…
Nov-07-24 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	Pliant Therapeutics to Participate in the Stifel Healthcare Conference (GlobeNewswire) +5.37%
Oct-17-24 08:00AM	Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting 2024 (GlobeNewswire)
Oct-04-24 09:03PM	Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc (GuruFocus.com)
Oct-01-24 04:35PM	Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs (GlobeNewswire) -5.89%
Sep-30-24 04:45PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-24 08:00AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer (GlobeNewswire)
Sep-10-24 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-26-24 09:10AM	Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 (GlobeNewswire)
Aug-07-24 11:53PM	PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 04:03PM	Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Jul-15-24 08:00AM	Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures (GlobeNewswire)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-13-24 04:05PM	Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors (GlobeNewswire)
Jun-12-24 04:05PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-24 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress (GlobeNewswire)
May-21-24 06:50PM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference (GlobeNewswire)
May-14-24 11:28AM	Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial (MT Newswires)
07:30AM	Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-07-24 08:35AM	Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating (MT Newswires)
08:00AM	Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress (GlobeNewswire)
06:59AM	RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk (MT Newswires)
May-06-24 09:55PM	PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) +7.11%
Apr-02-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Mar-27-24 10:23AM	Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference (GlobeNewswire)
Mar-12-24 07:30AM	Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Mar-07-24 10:00AM	Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline (Zacks)
Feb-27-24 04:03PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-07-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Feb-04-24 03:29PM	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis (GlobeNewswire)
Jan-19-24 08:28PM	Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares (GuruFocus.com) +5.57%
Jan-03-24 08:00AM	Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 04:30PM	Pliant Therapeutics Presentations at The Liver Meeting 2023 Highlight Bexotegrast, an Inhibitor of v 6 and v 1 Integrins, in Primary Sclerosing Cholangitis (GlobeNewswire) -7.09%
Nov-09-23 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire) -5.52%
08:44AM	Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season? (Zacks)
Nov-08-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-23 10:00AM	Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Nov-06-23 08:00AM	Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins v 8 and v 1 (GlobeNewswire)
Oct-31-23 04:03PM	Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) +5.16%
Oct-19-23 08:00AM	Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-16-23 04:05PM	Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer (GlobeNewswire)
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks)
Sep-27-23 10:52AM	Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study (Zacks)
09:01AM	Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-23 02:26PM	Rebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12 (TheStreet.com) +14.33%
12:10PM	Why Shares of Pliant Therapeutics Are Rising Tuesday (Motley Fool)
07:30AM	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis (GlobeNewswire)
Sep-25-23 04:05PM	Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis (GlobeNewswire)
Sep-15-23 08:00AM	Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer (GlobeNewswire)
Sep-11-23 08:00AM	Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023 (GlobeNewswire)
Aug-30-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 04:05PM	Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023 (GlobeNewswire)
10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-09-23 05:15PM	Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:03PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-25-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-23-23 07:30AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress (GlobeNewswire)
Jun-05-23 08:02PM	Over 100% Upside: Analysts See an Appealing Entry Point in These 2 Small-Cap Stocks (TipRanks)
06:19AM	Investors in Pliant Therapeutics (NASDAQ:PLRX) have seen splendid returns of 253% over the past year (Simply Wall St.)
May-24-23 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference (GlobeNewswire)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
May-10-23 08:05AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)

Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. It offers a product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coulie Bernard	President and CEO	Jan 17 '25	Sale	11.20	52,419	587,150	430,517	Jan 22 06:07 PM
Cummings Keith Lamont	Chief Financial Officer	Jan 17 '25	Sale	11.20	20,148	225,680	262,608	Jan 22 06:05 PM
Hull Hans	Chief Business Officer	Jan 17 '25	Sale	11.20	15,936	178,501	211,558	Jan 22 06:02 PM
Lefebvre Eric	Chief Medical Officer	Jan 17 '25	Sale	11.20	18,478	206,974	194,574	Jan 22 06:00 PM
Cheung Lily	Chief Human Resource Officer	Jan 17 '25	Sale	11.20	3,740	41,892	24,550	Jan 22 05:58 PM
Ouimette Mike	General Counsel & Corp. Sec'y	Jan 17 '25	Sale	11.20	13,270	148,639	80,774	Jan 22 05:55 PM
Ouimette Mike	General Counsel & Corp. Sec'y	Jan 22 '25	Sale	10.99	10,230	112,462	70,544	Jan 22 05:55 PM
MICHAEL OUIMETTE	Officer	Jan 22 '25	Proposed Sale	11.07	10,230	113,246		Jan 22 04:23 PM
Lefebvre Eric	Chief Medical Officer	Jul 10 '24	Sale	11.56	12,319	142,408	213,052	Jul 12 06:45 PM
Hull Hans	Chief Business Officer	Jul 10 '24	Sale	11.56	9,900	114,444	227,494	Jul 12 06:41 PM
Cummings Keith Lamont	Chief Financial Officer	Jul 10 '24	Sale	11.56	10,911	126,131	282,115	Jul 12 06:37 PM
Coulie Bernard	President and CEO	Jul 10 '24	Sale	11.56	38,710	447,488	482,936	Jul 12 06:22 PM
Ouimette Mike	General Counsel & Corp. Sec'y	Jul 10 '24	Sale	11.56	7,656	88,503	94,044	Jul 12 06:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLRX

Pliant Therapeutics Inc

Upgrade your FINVIZ experience